IN July 2018, the Food and Drug Administration (FDA) of the United States announced a recall of the anti-hypertensive angiotensin receptor blocker (ARB) valsartan because of contamination with a cancer-causing nitrosamine, N-nitrosodimethylamine (NDMA).
Initially affecting only one Chinese factory, the recall was then expanded and emulated by other regulatory bodies on companies and factories all over the world.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
